Arterius Limited

CAD symptoms can include chest pain and shortness of breath. A complete blockage of blood flow can lead to a heart attack. CAD and PAD are estimated to affect over 500m and 200m people around the world, respectively, and these numbers are increasing continuously. Traditional treatments for CAD and PAD have included endovascular interventions such as bypas...

Peripheral arterial disease (PAD) is estimated to affect over 200 million people around the world and this number is increasing continuously. Endovascular interventions with or without stenting are among the preferred treatment choices. Recent randomised controlled clinical trials have demonstrated the superiority of drug-coated balloon (DCB) therapy comp...

Arterius Ltd, a UK SME based in Leeds, and Afortiori Ltd, a UK based SME are planning to initiate first human trials of it's novel bioresorbable scaffold (stent) (BRS), ArterioSorb-BRS in 2019, having passed pre-clinical evaluations with an excellent data due to the support of the Innovate UK grants. ArterioSorb-BRS is designed to treat coronary artery di...

Peripheral vascular diseases (PVD) are caused by the formation of atherosclerotic plaques/blockages in arteries, which reduce blood supply to brain, heart, kidneys, liver/gut and limbs causing strokes, heart attacks, kidney failure and limb amputations. This condition is also known as peripheral artery occlusive disease or peripheral artery disease (PAD)....

The primary objective of this 2 year collaborative research project is to develop the world’s first resorbable osteoplasty for minimally invasive intramedullary stabilisation of osteoporotic bone fractures, which is a growing international healthcare problem that contributes to the £2.3bn annual cost of fractures to the NHS. In the UK, the population over...

ArterioSorb™ is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). CAD is the leading cause of death both in the UK and worldwide, responsible for more than 73,000 deaths in the UK each year. ArterioSorb™ is a next-generation bioresorbable cardiovascular scaff...

Increasing evidence is demonstrating that next generation biodegradable coronary stents are outperforming traditional permanently implanted drug eluting stents. Only two biodegradable stents are approved for sale within the EU, with several more in development. Manufacturing of polymer stents introduces significant challenges. Biodegradable polymeric sten...

The first three generations of cardiovascular permanent bare metal stent (BMS) and drug eluting stent (DES) technology have developed significantly over the last twenty years with advances in stent material, design and drug elution aimed at improving stent deliverability, safety and long term efficacy. However, the clinical performance of these permanent ...